Oncternal Therapeutics rises on cancer antibody study data

Oncternal Therapeutics

13/12/2021 14:25

** Shares of drug developer  ONCT.O  rise 5% to $2.90
premarket
    ** Company reports updated interim data from its ongoing
early- to mid-stage study testing its experimental antibody,
zilovertamab, with another cancer medication, ibrutinib, in
patients with mantle cell lymphoma (MCL) and chronic lymphocytic
leukemia (CLL)- cancers of the lymphatic system  urn:newsml:reuters.com:*:nGNX2nfB3X
    ** Study demonstrated cancer reduction in 81% of 26
evaluable MCL patients treated with the combination therapy, vs
historical rates of 66% for ibrutinib alone
    ** Median progression-free survival (PFS), measuring how
long the patient lives without the cancer getting worse, was
35.9 months for MCL patients on combo therapy vs historical PFS
of 12.8 months for ibrutinib monotherapy - company
    ** Says median PFS had not been reached for CLL patients
with 2 or lesser prior lines of therapy, and median PFS was 36.1
months for patients receiving more than 2 prior lines of therapy
    ** Company to present the data at the American Society of
Hematology (ASH) 2021 annual meeting
    ** Stock down 43.7% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))